We welcome the opportunity to work with clinical researchers who share our excitement in studying bavituximab, a first- in-class PS-targeting antibody currently in multiple clinical trials for oncology and viral diseases.

Current investigator-sponsored trials include:

• A Phase I/II trial evaluating bavituximab combined with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Click here to learn more about this trial.
• A Phase I/II trial evaluating bavituximab combined with cabazitaxel in patients with second-line castration resistant prostate cancer (CRPC). Click here to learn more about this trial
• A Phase I trial evaluating bavituximab combined with paclitaxel in patients with HER2-negative metastatic breast cancer. Click here to learn more about this trial.
• A Phase Ib trial evaluating bavituximab with pemetrexed and carboplatin in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Click here to learn more about this trial.

Click here to download our IST fact sheet.

Click here to download an IST application.